Skip to main content
FinSpry Logo
FinSpry
IPHA logo
IPHA
(NASDAQ)
Innate Pharma S.A.
$2.20-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Innate Pharma (IPHA) Stock Price & Financial Analysis

Innate Pharma Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$2.08 - $2.30
52-Week High$2.63
52-Week Low$1.17
Open$2.08
Volume29.50K
Average Volume (3M)115.94K
Market Cap181.87M
Shares Outstanding89.59M
Price to Sales (P/S)10.16
Price to Book (P/B)-7.21
EV/EBITDA-1.47
Revenue (TTM)17.90M
Net Income (TTM)-114.39M
Free Cash Flow (TTM)-72.03M
EPS (TTM)$-1.34
Profit Margin-638.90%
Operating Margin-681.46%
50-Day MA$1.44
200-Day MA$1.80
52-Week Change-38.79%
Annual Dividend$0.00
Dividend Yield0.00%

Frequently Asked Questions About Innate Pharma

What is the current stock price for IPHA?

As of the latest trading session, IPHA stock trades at $2.20. The 52-week range is $1.17–$2.63, with a day range of $2.08–$2.30.

What is the P/E ratio for IPHA?

The P/E ratio (Price-to-Earnings) for IPHA is shown in the Key Statistics section. This valuation metric helps compare Innate Pharma S.A. to industry peers.

Does IPHA pay dividends?

Innate Pharma does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for IPHA?

Based on 2 analysts, the consensus for IPHA is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of IPHA?

Innate Pharma's market capitalization is $197.1M, classifying it as a micro-cap company..